SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001628280-20-005759
Filing Date
2020-04-28
Accepted
2020-04-28 16:30:27
Documents
9
Period of Report
2020-05-31

Document Format Files

Seq Description Document Type Size
1 6-K auph-2020agm6xk.htm 6-K 17733
2 EXHIBIT 99.1 a9912020noticeofagsmofshar.htm EX-99.1 12094
3 EXHIBIT 99.2 a9922020noticeandaccess.htm EX-99.2 18428
4 EXHIBIT 99.3 a9932020informationcircular.htm EX-99.3 1357620
5 EXHIBIT 99.4 a9942020formofproxy.htm EX-99.4 1381
6 aupsedarproxy1.jpg GRAPHIC 7092511
7 aupsedarproxy2.jpg GRAPHIC 415409
8 aurinialogorbg031620v01.jpg GRAPHIC 121945
9 performancemap.jpg GRAPHIC 42869
  Complete submission text file 0001628280-20-005759.txt   11960896
Mailing Address #1203-4464 MARKHAM STREET VICTORIA BC A1 V8Z 7X8
Business Address #1203-4464 MARKHAM STREET VICTORIA BC A1 V8Z 7X8 250-708-4272
Aurinia Pharmaceuticals Inc. (Filer) CIK: 0001600620 (see all company filings)

IRS No.: 000000000 | State of Incorp.: A0 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-36421 | Film No.: 20825517
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences